PDS Biotechnology Corporation Common Stock (PDSB)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with what is proven. PDS Biotechnology has no revenue in the filed periods. In fiscal 2025, the year ended 2025-12-31, it lost $34.5 million, or $0.74 per diluted share. That was better than fiscal 2024's $37.6 million loss and -$1.03 per share, and fiscal 2023's $42.9 million loss and -$1.39 per share, so the loss trend is narrowing. But in fiscal Q1 2026, quarter ended 2026-03-31, the net loss was $7.3 million, or -$0.13 per share, and in fiscal Q2 2026, quarter ended 2026-06-30, it was $9.8 million, or -$0.18 per share. There is still no revenue, and trailing free cash flow is -$16.8 million, a -18.7% FCF yield on an $89.6 million market cap. At the close on 2026-10-13, price was $1.60. The FairStock P/E is -2.50, P/B is 7.87, ROE is -543.97%, ROCE is -70.59%, D/E is 1.83, Piotroski F-Score is 1/9, and Altman Z-Score is -33.54. Those are not the marks of a durable business with a margin of safety. The company's main asset appears to be its pipeline: PDS0101, a Versamune HPV candidate in Phase II for several HPV-related cancers, plus preclinical programs. That could be valuable, but I cannot verify a moat from the financials; it is a research bet funded by capital markets. FairStock's Lynch category is none because it lost money in each of the last four years. The loss trend and lean 21-employee structure are positives, but valuation rests on clinical outcomes, not earned profits. I would call this speculative, not investment-grade by Graham standards.

In plain English: PDS Biotechnology is a small clinical-stage biotech that is testing new cancer immunotherapies, mainly for HPV-related cancers. It has no product revenue and has lost money every year shown, so the business looks weak today. The stock has run up near the high end of its 52-week range, and by its current numbers it looks expensive rather than cheap because there are no profits or cash flow to support the price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer